Top

Published in:

01-02-2012 | Case Report

Epstein–Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma

Authors: Toshinari Yagi, Jun Ishikawa, Nana Aono, Yukiko Yamashita, Shinsuke Kusakabe, Tetsuhiro Yoshinami, Yuki Akazawa, Daisuke Sakai, Sachiko Yamamoto, Yuri Hamanaka, Hiroaki Masaie, Naotoshi Sugimoto, Hitoshi Yoshida, Yasuhiko Tomita, Fumio Imamura

Published in: International Journal of Hematology | Issue 2/2012

Abstract

A 56-year-old woman with Hodgkin-like adult T-cell leukemia/lymphoma was treated with allogeneic peripheral blood stem cell transplantation on 17 April 2009. She manifested a moderate fever on day 41. CT scanning and other examinations detected slightly swollen lymph nodes, and pathological findings of right axillary lymph nodes revealed an Epstein–Barr virus-associated post-transplant lymphoproliferative disorder. She was successfully treated with rituximab.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 281–4.

Ohshima K, Suzumiya J, Kato A, Tashiro K, Kikuchi M. Clonal HTLV-I-infected CD4⁺T-lymphocytes and non-clonal non-HTLV-I-infected giant cells in incipient ATLL with Hodgkin-like histologic features. Int J Cancer. 1997;72:592–8.PubMedCrossRef

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 343–9.

Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia–lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375–82.PubMedCrossRef

Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas’ hematopoietic cell transplantation. 4th ed. Wiley, Blackwell, Oxford; 2009. p. 1411.

Balink H, Collins J, Bruyn G, Gemmel F. F-18 FDG PET/CT in the diagnosis of fever of unknown origin. Clin Nucl Med. 2009;34(12):862–8.PubMedCrossRef

Curtis RE, Travis LB, Rowlings PA, Sociĕ G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–16.PubMed

Tanaka Y, Kondo T, Kishimoto W, Kanda J, Tashima M, Mizumoto C, et al. Epstein–Barr virus-associated B cell lymphoproliferative disorder complicated in adult T-cell leukemia. Rinshou Ketsueki. 2008;49:263–9.

Tobinai K, Ohtsu T, Hayashi M, Kinoshita T, Matsuno Y, Mukai K, et al. Epstein–Barr virus (EBV) genome carrying monoclonal B-cell lymphoma in a patient with adult T-cell leukemia–lymphoma. Leuk Res. 1991;15:837–46.PubMedCrossRef

10.

Kuehnle I, Huls MH, Liu Z, Semmelmann M, Krance RA, Brenner MK, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502–5.PubMed

11.

Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001;115:112–8.PubMedCrossRef

Title: Epstein–Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma
Authors: Toshinari Yagi
Jun Ishikawa
Nana Aono
Yukiko Yamashita
Shinsuke Kusakabe
Tetsuhiro Yoshinami
Yuki Akazawa
Daisuke Sakai
Sachiko Yamamoto
Yuri Hamanaka
Hiroaki Masaie
Naotoshi Sugimoto
Hitoshi Yoshida
Yasuhiko Tomita
Fumio Imamura
Publication date: 01-02-2012
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 2/2012
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-011-0979-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

A fatal case of cytomegalovirus ventriculoencephalitis in a mycosis fungoides patient who received multiple umbilical cord blood cell transplantations

Involvement of non-vascular stem cells in blood vessel formation

Irradiation induces homing of donor endothelial progenitor cells in allogeneic hematopoietic stem cell transplantation

Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux

Abnormal tumor vasculatures and bone marrow-derived pro-angiogenic cells in cancer

Interleukin-6-producing dermoid cyst associated with multicentric Castleman’s disease

Keynote webinar | Spotlight on antibody–drug conjugates in cancer